IN8bio announces positive preclinical data for nsCAR platform and launches INB-330 program at AACR 2023

IN8BIO, INC.

nsCAR platform showed ability to target cancer cells while sparing healthy tissue; ns19CAR killed 80% of leukemia cells vs 5% of healthy B cells.
Launched INB-330 program targeting CD33 in AML; ns33CAR demonstrated anti-leukemic activity against AML, B-ALL, and CML cell lines.
Data presented at AACR Annual Meeting 2023; management highlights potential to address previously 'undruggable' targets.
Company seeks potential partners for further evaluation of nsCAR platform with additional targets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.